18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
Primary Purpose
Hyperparathyroidism, Primary
Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
18F-Fluorocholine
Positron emission tomography (PET)
Sponsored by
About this trial
This is an interventional diagnostic trial for Hyperparathyroidism, Primary
Eligibility Criteria
Inclusion Criteria:
- Age >= 13 years.
- Biochemically proven hyperparathyroidism and an indication for surgery.
- Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria:
- Current Pregnancy.
- Patients unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
Sites / Locations
- University of California, San FranciscoRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Fluorocholine PET Imaging
Arm Description
Patients will undergo a single fluorocholine PET imaging study prior to surgery.
Outcomes
Primary Outcome Measures
Proportion of participants with true-positives (sensitivity) of 18F-Fluorocholine PET using sestamibi imaging
Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be correlated to the location at surgery. True positive will be defined as an adenoma on imaging in the same location as seen at surgery. Sensitivity will be reported by individual reader.
Proportion of participants with true-positives (sensitivity) of 18F-Fluorocholine PET using predefined threshold
Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology compared to a predefined threshold. Location of parathyroid adenoma at imaging as read by three blinded readers, will be correlated to the location at surgery. True positive will be defined as an adenoma on imaging in the same location as seen at surgery. Sensitivity will be reported by individual reader.
Secondary Outcome Measures
Detection rate of 18F-fluorocholine PET
The detection rate of 18F-fluorocholine PET in participants who have not undergone surgical resection will be reported
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04895631
Brief Title
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
Official Title
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2021 (Actual)
Primary Completion Date
June 30, 2026 (Anticipated)
Study Completion Date
June 30, 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Thomas Hope
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.
Detailed Description
PRIMARY OBJECTIVE:
I. To investigate the performance (accuracy) of 18F-fluorocholine PET in the detection of hyperfunctioning parathyroid glands in surgical patients with biochemically proven primary hyperparathyroidism.
OUTLINE:
Participants will receive a single dose of 18F-Fluorocholine at the time the participant undergoes a single imaging study using 18F-fluorocholine. Study related procedures will end after the study visit. Participants who undergo subsequent parathyroidectomy, will have the results reviewed and compared to the results from the imaging study
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperparathyroidism, Primary
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
140 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fluorocholine PET Imaging
Arm Type
Experimental
Arm Description
Patients will undergo a single fluorocholine PET imaging study prior to surgery.
Intervention Type
Drug
Intervention Name(s)
18F-Fluorocholine
Other Intervention Name(s)
Fluorocholine
Intervention Description
One-time injection of 4-7 millicurie (mCi)
Intervention Type
Procedure
Intervention Name(s)
Positron emission tomography (PET)
Other Intervention Name(s)
PET
Intervention Description
Imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
Primary Outcome Measure Information:
Title
Proportion of participants with true-positives (sensitivity) of 18F-Fluorocholine PET using sestamibi imaging
Description
Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be correlated to the location at surgery. True positive will be defined as an adenoma on imaging in the same location as seen at surgery. Sensitivity will be reported by individual reader.
Time Frame
Up to 1 year
Title
Proportion of participants with true-positives (sensitivity) of 18F-Fluorocholine PET using predefined threshold
Description
Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology compared to a predefined threshold. Location of parathyroid adenoma at imaging as read by three blinded readers, will be correlated to the location at surgery. True positive will be defined as an adenoma on imaging in the same location as seen at surgery. Sensitivity will be reported by individual reader.
Time Frame
Up to 1 year
Secondary Outcome Measure Information:
Title
Detection rate of 18F-fluorocholine PET
Description
The detection rate of 18F-fluorocholine PET in participants who have not undergone surgical resection will be reported
Time Frame
Up to 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age >= 13 years.
Biochemically proven hyperparathyroidism and an indication for surgery.
Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria:
Current Pregnancy.
Patients unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Daniel Thompson
Phone
415-514-8995
Email
fch@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Hope, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Thompson
Email
Daniel.Thompson@ucsf.edu
First Name & Middle Initial & Last Name & Degree
UCSF Fluorocholine Team
Phone
415-514-8995
Email
fch@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Thomas Hope, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
We'll reach out to this number within 24 hrs